Section to complete information about the inclusion and exclusion criteria for participant selection, including age and gender.
Inclusion criteria:
1.Adults of both genders. 2.Age between 18 and 60 years. 3.Clinical history of chronic hepatitis caused by hepatitis C virus (confirmed by liver biopsy in the last 12 months before starting the clinical study, anti-HCV positive by UMELISA VHC, HCV RNA positive by UMELOSA VHC). 4.Patients non-responders to previous treatment with IFN alpha-2b and Ribavirin. 5.HCV RNA genotype 1b. 6.Informed consent signed.
Exclusion criteria:
1.Positive to serum markers of infection with hepatitis A virus (HAV) or hepatitis B virus (HBV). 2. Positive to serum markers of infection human immunodeficiency virus (HIV-1, 2). 3.Patients with concomitant background liver disease of any other cause (alcoholism, autoimmune hepatitis, toxic, Wilson´s disease, haemochromatosis, obesity). 4.Women in fertile age that use hormone-based contraceptive methods. 5.Women and men in reproductive age without contraceptive control. 6.Pregnancy and breastfeeding. 7.Chronic no-compensated disease (high blood pressure, diabetes mellitus, chronic renal insufficiency, heart insufficiency, thyroid alterations, epilepsy, cancer, severe mind depression, etc.). 8.Patients with previous diagnosis of blood alterations (leukemia, hemophilia, and others). 9.Liver histology indicating cirrhosis or hepatocellular carcinoma. 10.Values in evaluations of clinical laboratory indicating alterations before start the treatment. 11.Concomitant immunosuppresive disease, consumption of immunosuppresive/ immunomodulators drugs (steroids, colony stimulating factor, etc.) in the six months previous to the study. 12.Documented autoimmune disease (systemic erithematosus lupus, reumatoid arthritis, multiple sclerosis, diabetes mellitus type I, etc.). 13.Patients with background of severe allergy (asthma degree III or IV, urticary, dermatitis, bronchitis, etc.). 14.Disease with fever (body temperature above >37.8°C) in the moment or 24 hours previous to the administration of the vaccine, or acute infectious disease suggested by clinical evaluation.